Trials / Completed
CompletedNCT04974749
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of REPLAGAL® in Treatment-naïve Chinese Subjects With Fabry Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 7 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks. Participants will visit their study clinic many times throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REPLAGAL | REPLAGAL IV infusion. |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2024-01-03
- Completion
- 2024-01-03
- First posted
- 2021-07-23
- Last updated
- 2024-10-08
- Results posted
- 2024-10-08
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04974749. Inclusion in this directory is not an endorsement.